The SLC26A6 antibody is a crucial tool for studying the solute carrier family 26 member 6 (SLC26A6), a transmembrane anion exchanger encoded by the *SLC26A6* gene. SLC26A6. also known as PAT1 or CFEX, facilitates the transport of chloride, bicarbonate, oxalate, sulfate, and other anions across epithelial cell membranes. It is prominently expressed in the apical membranes of the kidney, pancreas, and small intestine, where it plays a vital role in pH homeostasis, electrolyte balance, and oxalate secretion. Dysregulation of SLC26A6 is implicated in pathologies like kidney stones, pancreatic insufficiency, and metabolic disorders.
The SLC26A6 antibody, typically generated in rabbits or mice, targets specific epitopes of the protein, enabling its detection in techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Polyclonal antibodies are commonly used due to their high affinity for multiple antigenic sites. Validation often includes knockout controls or siRNA-based silencing to confirm specificity. Research applications focus on elucidating SLC26A6’s physiological roles in ion transport mechanisms, its interaction with other transporters (e.g., CFTR), and its contribution to disease pathways. Studies in rodent models and human tissues highlight its therapeutic potential in managing hyperoxaluria, diabetes, and digestive disorders. The antibody’s utility extends to drug development screens targeting anion exchange processes. Overall, it serves as a cornerstone for exploring SLC26A6’s multifaceted functions in health and disease.